Prosper Stars & Stripes, a protracted/quick fairness fund, not too long ago launched its second quarter 2025 investor letter. A replica of the letter could be downloaded right here. The fund underperformed and generated a web return of +9.6% in comparison with a complete return of +8.5% for the long-only small-cap Russell 2000 Index (the “Russell”), and a complete return of +5.0% for the lengthy/quick fairness hedge fund peer group represented by the HFRX Fairness Hedge Index (the “HFRX”). For the six months ended 2025, Prosper Stars & Stripes returned a web return of (0.8%) in comparison with (1.8%) for the Russell and +5.9% for the HFRI. The portfolio demonstrated robust outperformance relative to its web publicity through the quarter. Within the second quarter of 2025, US equities reversed the declines seen within the first quarter. As well as, please examine the fund’s prime 5 holdings to know its finest picks in 2025.
In its second-quarter 2025 investor letter, Prosper Stars & Stripes highlighted shares resembling Bio-Rad Laboratories, Inc. (NYSE:BIO). Bio-Rad Laboratories, Inc. (NYSE:BIO) is a medical machine firm, engages within the manufacturing and distribution of life science analysis and scientific diagnostic merchandise. The one-month return of Bio-Rad Laboratories, Inc. (NYSE:BIO) was 7.62%, and its shares misplaced 11.69% of their worth over the past 52 weeks. On August 29, 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) inventory closed at $297.88 per share, with a market capitalization of $7.858 billion.
Prosper Stars & Stripes acknowledged the next relating to Bio-Rad Laboratories, Inc. (NYSE:BIO) in its second quarter 2025 investor letter:
“One space the place we see explicit promise is bioprocessing, which we imagine is coming into a interval of extra sustained restoration. Our place in Bio-Rad Laboratories, Inc. (NYSE:BIO) displays this conviction. BIO’s valuation is underpinned by its roughly 38% possession stake in Sartorius, a world chief in bioprocessing, at the moment value about $5.5 billion. Adjusting for this stake, the core enterprise is at the moment buying and selling at roughly 6x FY2026 EBITDA, in comparison with friends that at the moment commerce at double and even triple that degree. On a extra normalized valuation a number of, the inventory would indicate a possible upside of greater than 40%. Encouragingly, current earnings outcomes demonstrated a stronger-than-anticipated dedication to revenue enchancment, and the corporate’s deliberate analyst day early subsequent 12 months might function a significant catalyst because the market reassesses its profitability trajectory.”
Bio-Rad Laboratories, Inc. (NYSE:BIO) will not be on our record of 30 Most Common Shares Amongst Hedge Funds. As per our database, 42 hedge fund portfolios held Bio-Rad Laboratories, Inc. (NYSE:BIO) on the finish of the second quarter, which was 36 within the earlier quarter. Whereas we acknowledge the potential of Bio-Rad Laboratories, Inc. (NYSE:BIO) as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back danger. In case you’re in search of an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
